newsfilter
← Latest News
Business Wire·

BeOne Medicines Announces Third Quarter 2025 Financial Results and Business Updates

Third quarter total revenues increased 41% to $1.4 billion versus third quarter 2024 Global BRUKINSA® (zanubrutinib) revenues increased 51% to $1.0 billion versus third quarter 2024 Diluted GAAP Earnings per